{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027003","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.686618+00:00","generated_at":"2026-06-21T21:46:51.891085+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeoVax Q3 net loss $3.97M; cash jumps to $34.7M; Phase 2 trials advance","bullets":["Net loss $3.97M ($0.17/sh) for Q3 2022 vs $1.95M ($0.31) in Q3 2021; 9-month net loss $8.64M.","Cash $34.7M at Sep 30, 2022 vs $11.4M at Dec 31, 2021; raised $27.7M from stock/warrant sales and $7.6M from warrant exercises.","Phase 2 COVID vaccine GEO-CM04S1 advancing; Lancet Microbe data show robust neutralizing antibodies and T cells; expanding sites.","Gedeptin Phase 1/2 for head and neck cancer expands to Emory and Thomas Jefferson; FDA orphan grant funded.","Secured rights to NIH-MVA for monkeypox/smallpox; began preclinical studies for pan-coronavirus and MUC1 immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027003","json":"https://secwatch.observer/filing/0001437749-22-027003.json","markdown":"https://secwatch.observer/filing/0001437749-22-027003.md","text":"https://secwatch.observer/filing/0001437749-22-027003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/0001437749-22-027003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/govx20221109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:46:51.891085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65a5b70c129be9744d9d4482006eb2c1652ca506","claim":"GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774922027003/0001437749-22-027003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}